Welcome to the August issue of The Pharmafile Brief, where we explore the key developments shaping healthcare over the past month.
In our second issue, we cover significant advances in cancer diagnostics, the NHS’s ongoing shift towards digitisation, and the unmet medical needs of patients living with Crohn’s disease and other autoimmune conditions. We also delve into the latest in psychiatry and mental health, spotlighting new drug candidates for depression and schizophrenia, and examining the complex relationship between sleep and well-being.
A highlight of this issue is our interview with Russell Bradley, President and General Manager of CNSide – a subsidiary of Plus Therapeutics – on the diagnosis and treatment of central nervous system cancer metastases. Russell gives us an insight into how these metastases originate, the current limitations of diagnostic tools and promising innovations improving both accuracy and patient outcomes.
We’re excited to launch our new series: The Pharma Files, featuring conversations with leaders across pharma and healthcare. They’ll share their perspectives on industry trends, the evolving challenges and opportunities ahead, and how they’re shaping the future of the field. In the first Q&A, we speak with Priyanka Hinton, Customer Solutions Director at CHASE, about the forces driving change in pharma and healthcare today –and what’s next for the industry.
This issue features an insightful article from Lilly UK, examining how patients with Crohn’s disease and other autoimmune conditions often face delays in receiving compassionate, effective care – a situation exacerbated by growing NHS demand and limited resources. Holly Thomas, Associate Vice President of Specialty Care at Lilly UK and Ireland, calls for immunology to be prioritised to better address these unmet needs.
We also continue our Gateway to Local Adoption series in partnership with Visions4Health, a market access consultancy. This third instalment features James Scott, Digital and Informatics Specialist Pharmacist, who shares his perspective on driving digital transformation in the NHS. He argues that real change will be led not by software alone, but by a skilled, supported and inspired workforce.
Finally, in recognition of National Wellness Month, our Five Facts for August focus on the links between sleep and mental health – from the correlation between sleep disorders and psychiatric conditions to how things like weighted blankets can support more restful sleep.
Also aligned with National Wellness Month, this issue covers the latest news on recent developments in psychiatry and neurology. New data published by the NHS Business Services Authority (NHSBSA) reveals that mental health prescriptions in England have reached an all-time high, with significant increases in antidepressants, ADHD medications and drugs for dementia. Regarding clinical trials, Seaport Therapeutics has dosed its first patient in its phase 2 study of a new treatment for major depressive disorder, which is expected to deliver rapid antidepressant and anti-anxiety effects. Meanwhile, Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration for a treatment to prevent relapse in adults with schizophrenia.
In neurology news, PharmNovo has submitted a clinical trial application to the Spanish health authorities for a new selective delta opioid receptor agonist – a potential non-addictive alternative for neuropathic pain. Additionally, Secarna Pharmaceuticals and Vect-Horus will collaborate to create new treatments for neurodegenerative and other central nervous system disorders, with the ability to cross the blood-brain barrier.
The industry saw a number of strategic leadership changes. Pharma intelligence solutions provider, Norstella, selected Kris Joshi as CEO and Jazz Pharmaceuticals appointed Renée Galá as CEO. Joachim Kreuzburg joined Cube Biotech’s board of directors, supporting its work in membrane protein production, and Cristian Massaces has been named executive vice president, chief medical officer and head of development at Bristol Myer Squibb.
We hope you enjoy reading this issue of The Pharmafile Brief. Look out for a new issue at the start of each month, with new, in-depth analysis across the pharma, biotech and healthcare industry.

Published on August 4th, 2025

Published on August 3rd, 2025

Published on August 3rd, 2025

Published on August 3rd, 2025

Published on July 30th, 2025
Published on July 29th, 2025

Published on July 28th, 2025

Published on July 25th, 2025

Published on July 18th, 2025

Published on July 16th, 2025

Published on July 14th, 2025

Published on July 11th, 2025

Published on July 10th, 2025

Published on July 1st, 2025